SEC Form 4 · accession 0001992908-26-000011
LB PHARMACEUTICALS INC · LBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert A. Lenz
Director
Period of report
Jun 3, 2026
Accepted (ET)
Jun 5, 2026 · 5:26 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001691082
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $27.95 | Jun 3, 2026 | A | 12,500 | A | — | Jun 2, 2036 | Common Stock | 12,500 | 12,500 | D |
Explanation of responses
- F1Includes an option award for 2,500 shares pursuant to the Issuer's non-employee director compensation policy which represents a prorated annual grant for the previous year.
- F2100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.